Latest quarter
Amgen reported Q3 FY2026 revenue of $10.4 billion, above the consensus of $10.0 billion. Adjusted earnings per share were $6.45, compared with the consensus estimate of $5.74.
Revenue increased from $9.6 billion a year earlier. Amgen’s filing said product sales growth was driven by volume, with Repatha among the medicines contributing to higher purchases. Repatha sales reached $1.1 billion, while the company’s rare-disease portfolio generated $1.6 billion in sales.
The filing said biosimilar launches contributed to declines in Prolia and XGEVA sales. Amgen reported Prolia sales of $632.0 million and XGEVA sales of $288.0 million.
Gross margin rose to 73.1% from 67.8%, and operating margin increased to 35.8% from 26.4%. The filing attributed lower operating expenses in part to reduced amortization of acquisition-related assets and the prior-year impact of Otezla impairment charges. Free cash flow was $3.7 billion, down from $4.2 billion a year earlier.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $10.4 billion | $9.6 billion | 8.45% |
| Diluted EPS | $7.08 | $5.93 | 19.3% |
| Gross margin | 73.1% | 67.8% | 5.4 percentage points |
| Operating margin | 35.8% | 26.4% | 9.4 percentage points |
| Free cash flow | $3.7 billion | $4.2 billion | −14.0% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $6.45 | $5.74 | Beat by 12.4% |
| Revenue | $10.4 billion | $10.0 billion | Beat by 4.14% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
Chief executive Robert Bradway said Amgen’s six key growth drivers grew 27% year over year and represented over 70% of third-quarter product sales. He identified Repatha, EVENITY and TEZSPIRE as medicines addressing disease areas where many patients remain untreated.
Bradway said Amgen increased research and development investment by 11% year over year and invested $600.0 million in capital expenditures during the quarter. He also said MariTide was advancing through Phase III development. CFO Thomas Dittrich said Amgen continued to expect a full-year non-GAAP operating margin of roughly 45.0% to 46.0% of product sales and expected operating expenses to rise sequentially in the fourth quarter.
Asked about IMDELLTRA, executive Murdo Gordon said an FDA-approved reduction in monitoring time for its existing second-line use was helping community oncology clinics initiate treatment. He said monitoring in the DeLLphi-305 study was shorter still and expressed hope that the label could improve further if the medicine is extended to frontline maintenance. Gordon said Amgen was working on regulatory filings and approvals.
When pressed on the commercial opportunity, Gordon said Amgen does not issue product-specific guidance. He said the addressable population changes by treatment setting and that patients in the earlier setting could remain on treatment longer.
Analysts also asked about dazodalibep in Sjögren’s disease. Executive James Bradner said results from the systemic study were difficult to read across to the symptomatic study because the patient populations differ. He said Amgen expected to have more to say after seeing the symptomatic-study data in the fourth quarter.
On MariTide access, Gordon said he expected reimbursement outside the U.S. to be tougher and hoped outcomes and diabetes data would help Amgen secure coverage in markets abroad.
Guidance
Amgen raised its FY2026 revenue guidance to $38.9 billion–$39.7 billion and its non-GAAP earnings-per-share outlook to $22.90–$23.70. The company also raised its GAAP earnings-per-share guidance to $18.34–$19.28.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Operating margin, Non Gaap, product Sales | FY2027 | Amgen does not expect its FY2027 operating margin to decline from its FY2026 guidance. | — | — |
| Share repurchases | FY2026 | $3.0 billion | $3.0 billion | Held |
| Tax rate, non-GAAP | FY2026 | 15.0%–16.5% | 15.0%–16.5% | Held |
| Revenue, Other Revenue | FY2026 | $1.9 billion | — | New |
| Operating expenses, Sga | Q4 FY2026 | Amgen expects higher SG&A expense sequentially in Q4 FY2026. | — | — |
| Operating expenses | Q4 FY2026 | Amgen expects a meaningful sequential increase in operating expenses in Q4 FY2026. | — | — |
| Operating margin, Non Gaap, product Sales | FY2026 | 45.0%–46.0% | — | New |
| EPS, non-GAAP | FY2026 | $22.90–$23.70 | $22.30–$23.50 | Raised |
| Revenue | FY2026 | $38.9 billion–$39.7 billion | $38.2 billion–$39.4 billion | Raised |
| Capex | FY2026 | $2.6 billion | $2.6 billion | Held |
| Customers, Repatha | FY2026 | 3,000,000 | — | — |
| Tax rate, GAAP | FY2026 | 14.5%–16.0% | 14.5%–16.0% | Held |
| EPS, GAAP | FY2026 | $18.34–$19.28 | $15.80–$17.08 | Raised |
| Revenue, Other | FY2026 | $1.9 billion | — | New |
| Operating margin, Non Gaap Product Sales | FY2026 | 45.0%–46.0% | — | New |